Medical Oncology

, Volume 27, Issue 2, pp 262–267 | Cite as

CHOP-21 for unfavorable Hodgkin’s lymphoma. An exploratory study

  • Jan Walewski
  • Elżbieta Lampka
  • Joanna Tajer
  • Włodzimierz Osiadacz
  • Ewa Kraszewska
  • Jolanta B. Krzyżanowska
  • Janusz Meder
Original Paper

Abstract

ABVD remains a standard chemotherapy for Hodgkin Lymphoma (HL) despite many efforts to demonstrate the superiority of other regimens. Bleomycin was proven marginally active in this combination (J Clin Oncol 22:1532–3, 2004) but adding significant toxicity. Response to ABVD is often slow and relapse rate of 20–30% is a concern. ABVD has never been directly compared to CHOP, the other global standard for other lymphomas that is composed of agents certainly active in HL. Current study is an update on our initial report of 2004 (Blood 104, 2004). In addition to extending the follow-up, we compared outcome after CHOP in a pilot series of previously untreated patients with a retrospective results of ABVD therapy at our institution. CR/CRu rates were 88 and 62% for CHOP and ABVD, respectively. In CHOP CS III/IV group, more patients had at least three risk factors (80%) than in ABVD CS III–IV group (40%). In contrast to ABVD, there were no deaths in CHOP group, but EFS was inferior. This might result from a higher risk level in CHOP patients. Toxicity of both regimens was mild: grade 3/4 leukopenia in 9%, grade 1/2/3 peripheral neuropathy in 6% of ABVD patients, and grade 3/4 neutropenia in 7% of CHOP patients. In conclusion, CHOP-21 is an active and low-toxic regimen in HL with risk factors. A prospective comparison of CHOP with a standard chemotherapy in a randomized study will be justified.

Keywords

Hodgkin lymphoma Risk factors CHOP chemotherapy 

References

  1. 1.
    Canellos GP, Duggan D, Johnson J, Niedzwiecki D. How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? J Clin Oncol. 2004;22:1532–3. doi:10.1200/JCO.2004.99.010.CrossRefPubMedGoogle Scholar
  2. 2.
    Walewski J, Lampka E, Kraszewska E, Osiadacz W, Tajer J, Konecki R, et al. CHOP chemotherapy for unfavorable or advanced Hodgkin’s Lymphoma. A pilot study. Blood (ASH Annual Meeting Abstracts) 2004;104, Abstract 1311.Google Scholar
  3. 3.
    Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol. 2005;23:7614–20. doi:10.1200/JCO.2005.02.7243.CrossRefPubMedGoogle Scholar
  4. 4.
    Lev DC, Onn A, Melinkova VO, Miller C, Stone V, Ruiz M, et al. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol. 2004;22:2092–100. doi:10.1200/JCO.2004.11.070.CrossRefPubMedGoogle Scholar
  5. 5.
    Johnson PW, Radford JA, Cullen MH, Sydes MR, Walewski J, Jack AS, et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin’s lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial. J Clin Oncol. 2005;23:9208–18. doi:10.1200/JCO.2005.03.2151.CrossRefPubMedGoogle Scholar
  6. 6.
    Walewski J, Tajer J, Lampka E, Kraszewska E, Osiadacz W, Meder J. CHOP-21 for Hodgkin’s lymphoma. An exploratory evaluation in comparison to ABVD at a single institution. Haematologica 2007;92 (S1):65, Abstract 0181.Google Scholar
  7. 7.
    Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. N Engl J Med. 1998;339:1506–14. doi:10.1056/NEJM199811193392104.CrossRefPubMedGoogle Scholar
  8. 8.
    Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17 (4):1244.Google Scholar
  9. 9.
    Montoto S, Camós M, López-Guillermo A, Bosch F, Cervantes F, Blandé J, et al. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease. Cancer. 2000;88:2142–8. doi:10.1002/(SICI)1097-0142(20000501)88:9<2142::AID-CNCR21>3.0.CO;2-M.CrossRefPubMedGoogle Scholar
  10. 10.
    Sieber M, Tesch H, Pfistner B, Rueffer U, Paulus U, Munker R, et al. Treatment of advanced Hodgkin’s disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin’s Lymphoma Study Group HD6 trial. Ann Oncol. 2004;15:276–82. doi:10.1093/annonc/mdh046.CrossRefPubMedGoogle Scholar
  11. 11.
    Federico M, Luminari S, Iannitto E, Polimeno G, Marcheselli L, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi trial. J Clin Oncol. 2008;27:805–11. doi:10.1200/JCO.2008.17.0910.CrossRefGoogle Scholar
  12. 12.
    Kolstad A, Nome O, Delabie J, Lauritzsen GF, Fossa A, Holte H. Standard CHOP-21 as first line therapy for elderly patients with Hodgkin’s lymphoma. Leuk Lymphoma. 2007;48:570–6. doi:10.1080/10428190601126610.CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2009

Authors and Affiliations

  • Jan Walewski
    • 1
  • Elżbieta Lampka
    • 1
  • Joanna Tajer
    • 1
  • Włodzimierz Osiadacz
    • 1
  • Ewa Kraszewska
    • 2
  • Jolanta B. Krzyżanowska
    • 1
  • Janusz Meder
    • 1
  1. 1.The Maria Skłodowska-Curie Memorial Institute and Cancer CentreWarszawaPoland
  2. 2.Medical Center for Postgraduate EducationWarszawaPoland

Personalised recommendations